Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2651 to 2700 of 3765 results for treatment

  1. Pharmacological therapy for advanced liver fibrosis in children and young people:- What is the clinical and cost effectiveness of pharmacological therapy in children and young people with advanced liver fibrosis?

    at risk of developing advanced stages of liver disease. Pharmacological treatment (for example, pioglitazone or vitamin E) could prevent...

  2. Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)

    This guidance has been updated and replaced by NICE guideline CG81.

  3. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35)

    This guidance has been updated and replaced by NICE technology appraisal guidance 373.

  4. Is acupuncture effective in reducing alcohol consumption compared with standard care?

    notes(if applicable) Why this is important:- Non-pharmacological treatments are an important therapeutic option for people with...

  5. Transperineal template biopsy and mapping of the prostate (IPG364)

    Evidence-based recommendations on transperineal template biopsy of the prostate. This involves inserting many fine needles though the skin between the scrotum and the anus in order to obtain tissue samples from the prostate for testing.

  6. Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction (IPG436)

    Evidence-based recommendations on percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction. This involves implanting a replacement valve with a wire mesh tube called a stent.

  7. Partial left ventriculectomy (the Batista procedure) (IPG41)

    Evidence-based recommendations on partial left ventriculectomy. This involves reducing the size of a part of the heart so it can pump blood more efficiently.

  8. Metatarsophalangeal joint replacement of the hallux (IPG140)

    Evidence-based recommendations on metatarsophalangeal joint replacement of the hallux. This involves removing the problem joint and replacing it with an artificial one.

  9. Artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure (IPG602)

    Evidence-based recommendations on artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure. This involves replacing the 2 lower chambers of the heart with a mechanical device to improve circulation until heart transplantation.

  10. Xpert Carba-R to identify people carrying carbapenemase-producing organisms (MIB52)

    NICE has developed a medtech innovation briefing (MIB) on the Xpert Carba-R to identify people carrying carbapenemase-producing organisms

  11. What methods are most effective for assessing and diagnosing the presence and severity of alcohol misuse in children and young people?

    the NHS to both assess the severity of the alcohol misuse and to guide treatment decisions. No similar well-developed measures exist for...

  12. Are there subgroups of people with Graves' disease who have a particularly good response to antithyroid drugs?

    that continued follow-up of people who have undergone radioactive iodine treatment was important and the 'as low as reasonably...

  13. What is the clinical and cost effectiveness of dosimetry-guided radioactive iodine strategies for hyperthyroidism?

    that continued follow-up of people who have undergone radioactive iodine treatment was important and the 'as low as reasonably...

  14. What is the long-term clinical and cost effectiveness, including safety, of radioactive iodine for hyperthyroidism?

    that continued follow-up of people who have undergone radioactive iodine treatment was important and the 'as low as reasonably...

  15. Mucoactive agents:- What is the most clinically and cost-effective dose of rhDNase (dornase alfa; recombinant human deoxyribonuclease) for people with cystic fibrosis?

    important- People with cystic fibrosis often have complex treatment schedules, which can include multiple nebulised...

  16. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries (IPG762)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries. This involves keyhole abdominal surgery. The aim is to stimulate and possibly strengthen the diaphragm to help people breathe without a ventilator.

  17. Implantation of a corneal graft–keratoprosthesis for severe corneal opacity in wet blinking eyes (IPG534)

    Evidence-based recommendations on implantation of a corneal graft–keratoprosthesis for severe corneal opacity in wet blinking eyes. This involves inserting an artificial cornea surrounded by a corneal graft from a human donor.

  18. Open prenatal repair for open neural tube defects in the fetus (IPG668)

    Evidence-based recommendations on open prenatal repair of open neural tube defects in the fetus. This involves open surgery through the woman’s abdomen to close the gap in the baby’s spine.

  19. Endoanchoring systems in endovascular aortic aneurysm repair (IPG725)

    Evidence-based recommendations on endoanchoring systems in endovascular aortic aneurysm repair. This involves using an anchoring device to hold a stent in place to prevent leaks in an aneurysm repair.

  20. Sexual health (QS178)

    This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.

  21. Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)

    This guidance has been updated and replaced by NICE technology appraisal guidance 766.

  22. Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)

    In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008

  23. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia (TA132)

    This guidance has been updated and replaced by NICE technology appraisal guidance 385.

  24. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    In development Reference number: GID-TA11365 Expected publication date: TBC

  25. Prevalence of anaphylactic reactions and related outcomes:- What is the annual incidence of anaphylaxis and its related outcomes within the UK?

    misclassification of milder reactions. Data should also be collected on any emergency treatment that was delivered (by a clinician, use...

  26. What is the annual incidence of anaphylaxis and its related outcomes within the UK?

    misclassification of milder reactions. Data should also be collected on any emergency treatment that was delivered (by a clinician, use...

  27. Thiazide: In people with acute heart failure and persistent congestion, does the addition of a thiazide diuretic to standard therapy lead to greater diuresis compared with adding placebo to standard therapy?

    hospital for treatment of decompensated heart failure. One of the most common and difficult to manage problems arising during the...

  28. Routine outcome measurement:- In people with a common mental health disorder, what is the clinical utility of routine outcome measurement and is it cost effective compared with standard care?

    improved treatment outcomes, because of its impact on healthcare professionals' behaviour and the prompter availability of appropriate...

  29. SecurAcath for securing cerebrospinal fluid catheters (MIB107)

    NICE has developed a medtech innovation briefing (MIB) on SecurAcath for securing cerebrospinal fluid catheters .

  30. Adults' uptake of and engagement with interventions for social anxiety disorder:- What methods are effective in improving uptake of and engagement with interventions for adults with social anxiety disorder?

    of people with social anxiety disorder never receive treatment; of those who do receive treatment many wait 10 years or...

  31. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1071.

  32. Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

    In development Reference number: GID-TA10935 Expected publication date: TBC

  33. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development Reference number: GID-TA11569 Expected publication date: TBC

  34. Smart Peak Flow for monitoring asthma (MIB282)

    NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .

  35. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (HTG348)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).

  36. For people with moderate and severe alcohol dependence who have significant comorbid problems, is an intensive residential rehabilitation programme clinically and cost effective when compared with intensive community-based care?

    those with severe problems and complex comorbidities, do not benefit from treatment and/or lose contact with services. One common...

  37. Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]

    In development Reference number: GID-TA11663 Expected publication date: TBC

  38. Endoscopic transsphenoidal pituitary adenoma resection (IPG32)

    Evidence-based recommendations on endoscopic transsphenoidal pituitary adenoma resection. This involves inserting a tube into the nostril towards the tumour base and removing the tumour using specialised surgical instruments.

  39. Implantation of accommodating intraocular lenses for cataract (IPG209)

    Evidence-based recommendations on implantation of accommodating intraocular lenses for cataract. This involves removing the clouded natural lens of the eye and replacing it with an accommodating lens to allow focusing on near and distant objects.

  40. What methods can improve the identification of women at high risk of postpartum psychosis and reduce this risk?

    increased risk of mortality in both the woman and her baby. Prophylactic treatment can be effective for women who are known to be at...

  41. Dopamine: In people with acute heart failure, congestion and worsening renal function, does the addition of low‑dose dopamine to standard therapy lead to greater diuresis and renal protection compared with adding placebo to standard therapy?

    clinically and cost effective decongestion in people admitted to hospital for treatment of decompensated heart failure. The study should...

  42. Corneal implants for the correction of refractive error (IPG225)

    Evidence-based recommendations on corneal implants for the correction of refractive error. This involves inserting clear plastic implants into the cornea to restore eyesight in short-sightedness.

  43. Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people with high-grade transformation of follicular lymphoma, which biological and clinical factors predict good outcomes with immunochemotherapy alone?

    likely to do well with conventional treatment (such as R-CHOP) and which people may benefit from intensive treatment with,...

  44. Postnatal care (NG194)

    This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.

  45. Twin and triplet pregnancy (NG137)

    This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.

  46. Behaviour change: digital and mobile health interventions (NG183)

    This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.

  47. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  48. Laparoscopic partial nephrectomy (IPG151)

    Evidence-based recommendations on laparoscopic partial nephrectomy. This involves making small ‘keyhole’ openings, either in the back or in the abdomen, to remove the section of kidney that contains the tumour.

  49. Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (TA202)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.